Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Niche competition and cancer metastasis to bone.

Schuettpelz LG, Link DC.

J Clin Invest. 2011 Apr;121(4):1253-5. doi: 10.1172/JCI57229. Epub 2011 Mar 23.

2.

Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models.

Wang N, Docherty FE, Brown HK, Reeves KJ, Fowles AC, Ottewell PD, Dear TN, Holen I, Croucher PI, Eaton CL.

J Bone Miner Res. 2014 Dec;29(12):2688-96. doi: 10.1002/jbmr.2300.

3.

Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.

Sun YX, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman NI, Koh-Paige AJ, Shim H, Pienta KJ, Keller ET, McCauley LK, Taichman RS.

J Bone Miner Res. 2005 Feb;20(2):318-29. Epub 2004 Nov 16.

4.

CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.

Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD, Cher ML.

Prostate. 2006 Jan 1;66(1):32-48.

PMID:
16114056
5.

Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone.

Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK.

Cancer Res. 2002 Mar 15;62(6):1832-7.

6.

The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.

Miwa S, Mizokami A, Keller ET, Taichman R, Zhang J, Namiki M.

Cancer Res. 2005 Oct 1;65(19):8818-25.

7.

The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches.

Ă–zdemir BC, Hensel J, Secondini C, Wetterwald A, Schwaninger R, Fleischmann A, Raffelsberger W, Poch O, Delorenzi M, Temanni R, Mills IG, van der Pluijm G, Thalmann GN, Cecchini MG.

PLoS One. 2014 Dec 8;9(12):e114530. doi: 10.1371/journal.pone.0114530. eCollection 2014.

8.

Pathogenesis of osteoblastic bone metastases from prostate cancer.

Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D.

Cancer. 2010 Mar 15;116(6):1406-18. doi: 10.1002/cncr.24896. Review. Erratum in: Cancer. 2010 May 15;116(10):2503.

9.

Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression.

Perissinotto E, Cavalloni G, Leone F, Fonsato V, Mitola S, Grignani G, Surrenti N, Sangiolo D, Bussolino F, Piacibello W, Aglietta M.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):490-7.

10.

Prostate cancer cells promote osteoblastic bone metastases through Wnts.

Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET.

Cancer Res. 2005 Sep 1;65(17):7554-60.

11.

Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis.

Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, Beider K, Avniel S, Kasem S, Galun E, Peled A.

FASEB J. 2004 Aug;18(11):1240-2. Epub 2004 Jun 4.

PMID:
15180966
12.

The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis.

Wang J, Loberg R, Taichman RS.

Cancer Metastasis Rev. 2006 Dec;25(4):573-87. Review.

PMID:
17165132
13.

Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions.

Yonou H, Ochiai A, Goya M, Kanomata N, Hokama S, Morozumi M, Sugaya K, Hatano T, Ogawa Y.

Prostate. 2004 Mar 1;58(4):406-13.

PMID:
14968441
14.

The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases?

Hirbe AC, Morgan EA, Weilbaecher KN.

Curr Pharm Des. 2010;16(11):1284-90. Review.

PMID:
20166978
15.

A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma.

Geminder H, Sagi-Assif O, Goldberg L, Meshel T, Rechavi G, Witz IP, Ben-Baruch A.

J Immunol. 2001 Oct 15;167(8):4747-57.

16.

Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.

Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P, Huard J, Lieberman JR.

J Bone Miner Res. 2005 Dec;20(12):2189-99. Epub 2005 Aug 1.

17.

COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems.

Katoh H, Hosono K, Ito Y, Suzuki T, Ogawa Y, Kubo H, Kamata H, Mishima T, Tamaki H, Sakagami H, Sugimoto Y, Narumiya S, Watanabe M, Majima M.

Am J Pathol. 2010 Mar;176(3):1469-83. doi: 10.2353/ajpath.2010.090607. Epub 2010 Jan 28.

18.

The role of osteoblasts in regulating hematopoietic stem cell activity and tumor metastasis.

Neiva K, Sun YX, Taichman RS.

Braz J Med Biol Res. 2005 Oct;38(10):1449-54. Epub 2005 Sep 6. Review.

19.

Current trials using bone-targeting agents in prostate cancer.

Tu SM, Lin SH.

Cancer J. 2008 Jan-Feb;14(1):35-9. doi: 10.1097/PPO.0b013e318161d32d. Review. Erratum in: Cancer J. 2008 May-Jun;14(3):199.

PMID:
18303481
20.

Tumor-stromal interactions in bone metastasis.

Nannuru KC, Singh RK.

Curr Osteoporos Rep. 2010 Jun;8(2):105-13. doi: 10.1007/s11914-010-0011-6. Review.

PMID:
20425618

Supplemental Content

Support Center